{
  "url": "https://openlegislation.uk/eu-decision-2020-1729/annex/part-A/division-5/division-5.1",
  "json_url": "https://openlegislation.uk/eu-decision-2020-1729/annex/part-A/division-5/division-5.1.json",
  "legislation": "eudn/2020/1729",
  "legislation_title": "Commission Implementing Decision (EU) 2020/1729 of 17 November 2020 on the monitoring and reporting of antimicrobial resistance in zoonotic and commensal bacteria and repealing Implementing Decision 2013/652/EU (notified under document C(2020) 7894) (Only the English version is authentic) (Text with EEA relevance)",
  "legislation_url": "https://openlegislation.uk/eu-decision-2020-1729",
  "path": "annex/part/A/division/5/division/5.1",
  "kind": "division",
  "number": "5.1",
  "heading": "Methods for detection of presumptive ESBL- or AmpC- or CP-producing E. coli",
  "text": "For the purpose of estimating the proportion of samples containing presumptive ESBL- or AmpC- or CP-producing E. coli among the caecal and fresh meat samples collected in accordance with point 1(d), the laboratories referred to in Article 3(2) shall use detection methods detailed in the protocols of the EURL for AMR.\nAll presumptive ESBL- or AmpC- or CP-producing E. coli isolates identified through the methods referred to in above shall be tested with the first panel and the second panel of antimicrobial substances in accordance with Table 2 and Table 5 respectively.\nTable 5\nPanel of antimicrobial substances, EUCAST epidemiological cut-off values (ECOFFs) and clinical resistance breakpoints and concentrations ranges to be used for testing only Salmonella spp. and E. coli isolates resistant to cefotaxime or ceftazidime or meropenem – (Second panel)\nNA: not available\nAntimicrobial\nClass of antimicrobial\nSpecies\nInterpretative thresholds of AMR (mg/L)\nRange of concentrations (mg/L)(No of wells in brackets)\nECOFF\nClinical breakpoint\nCefepime\nCephalosporin\nSalmonella\nNA\n> 4\n0,06-32 (10)\nE. coli\n> 0,125\n> 4\nCefotaxime\nCephalosporin\nSalmonella\n> 0,5\n> 2\n0,25-64 (9)\nE. coli\n> 0,25\n> 2\nCefotaxime + clavulanic acid\nCephalosporin/beta-lactamase inhibitor combination\nSalmonella\nNA\nNA\n0,06-64 (11)\nE. coli\n> 0,25\nNA\nCefoxitin\nCephamycin\nSalmonella\n> 8\nNA\n0,5-64 (8)\nE. coli\n> 8\nNA\nCeftazidime\nCephalosporin\nSalmonella\n> 2\n> 4\n0,25-128 (10)\nE. coli\n> 0,5\n> 4\nCeftazidime + clavulanic acid\nCephalosporin//beta-lactamase inhibitor combination\nSalmonella\nNA\nNA\n0,125-128 (11)\nE. coli\n> 0,5\nNA\nErtapenem\nCarbapenem\nSalmonella\nNA\n> 0,5\n0,015-2 (8)\nE. coli\nNA\n> 0,5\nImipenem\nCarbapenem\nSalmonella\n> 1\n> 4\n0,12-16 (8)\nE. coli\n> 0,5\n> 4\nMeropenem\nCarbapenem\nSalmonella\n> 0,125\n> 8\n0,03-16 (10)\nE. coli\n> 0,125\n> 8\nTemocillin\nPenicillin\nSalmonella\n> NA\nNA\n0,5-128 (9)\nE. coli\n> 16\nNA",
  "extent": "E+W+S+N.I.",
  "status": null,
  "version": "current",
  "annotations": [
    {
      "type": "footnote",
      "label": "f1",
      "text": "https://www.eurl-ar.eu/protocols.aspx"
    }
  ],
  "outstanding_effects": [],
  "provenance": {
    "source": "legislation.gov.uk",
    "source_url": "https://www.legislation.gov.uk/eudn/2020/1729/annex/part/A/division/5/division/5.1",
    "retrieved_at": "2026-11-01T15:12:05.159169+00:00"
  },
  "licence": "Open Government Licence v3.0",
  "licence_url": "https://www.nationalarchives.gov.uk/doc/open-government-licence/version/3/",
  "attribution": "Contains public sector information licensed under the Open Government Licence v3.0. Source: legislation.gov.uk, The National Archives."
}